RCEL
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Valuation is distorted by negative equity and lack of profitability.
- Moderate Price/Sales ratio (2.20)
- Negative Price/Book ratio
- Negative Forward P/E
- No Graham Number available due to lack of earnings
Growth metrics are currently negative, contradicting analyst 'Strong Buy' ratings.
- Strong analyst price targets
- High gross margin potential
- Negative YoY revenue growth
- Consistent earnings misses
Long-term historical performance is overwhelmingly bearish.
- Recent 1-month price bounce
- 5-year return of -74.5%
- Consistent failure to meet EPS estimates
Piotroski score is the only stabilizing metric; liquidity ratios are in distress.
- Piotroski F-Score of 5/9 (Stable)
- Current Ratio < 1.0 (0.57)
- Negative Book Value
- ROA of -39.06%
Non-dividend paying growth/speculative stock.
- No dividend paid
- No dividend history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for RCEL and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
RCEL
AVITA Medical, Inc.
Primary
|
-74.5% | -65.7% | -44.2% | +28.8% | +22.7% | +2.6% |
|
HRTX
Heron Therapeutics, Inc.
Peer
|
-94.8% | -68.8% | -53.1% | -33.4% | -12.1% | +6.6% |
|
QIPT
Quipt Home Medical Corp
Peer
|
-44.7% | -42.7% | +56.0% | +34.2% | +1.1% | 0.0% |
|
ACH
Accendra Health, Inc.
Peer
|
-92.8% | -89.2% | -85.8% | -73.2% | -22.1% | -16.3% |
|
QTRX
Quanterix Corporation
Peer
|
-94.1% | -71.3% | -32.0% | -40.3% | -22.6% | +4.2% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
RCEL
AVITA Medical, Inc.
|
BEARISH | $157.45M | - | -% | -67.8% | $5.14 | |
|
HRTX
Heron Therapeutics, Inc.
|
BEARISH | $160.82M | - | -% | -13.0% | $0.85 | Compare |
|
QIPT
Quipt Home Medical Corp
|
BEARISH | $162.3M | - | -9.3% | -4.0% | $3.65 | Compare |
|
ACH
Accendra Health, Inc.
|
BEARISH | $163.2M | - | -196.4% | -12.4% | $2.11 | Compare |
|
QTRX
Quanterix Corporation
|
BEARISH | $164.29M | - | -34.2% | -77.1% | $3.5 | Compare |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning RCEL from our newsroom.